GCM
CDMO

Geneva Capital Management’s Avid Bioservices, Inc. Common Stock CDMO Stock Holding History

Geneva Capital Management’s Portfolio CDMO Stock Details CDMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-2,258,671
Closed -$21.3M – 128
2023
Q3 		$21.3M Sell
2,258,671
-61,299
-3% -$738K 0.45% 72
2023
Q2 		$32.4M Sell
2,319,970
-5,939
-0.3% -$101K 0.64% 59
2023
Q1 		$43.6M Buy
2,325,909
+489,128
+27% +$8.03M 0.89% 46
2022
Q4 		$25.3M Buy
1,836,781
+396,417
+28% +$6.07M 0.57% 66
2022
Q3 		$27.5M Buy
1,440,364
+74,014
+5% +$1.35M 0.64% 62
2022
Q2 		$20.9M Sell
1,366,350
-24,840
-2% -$367K 0.48% 82
2022
Q1 		$28.3M Buy
+1,391,190
New +$28.3M 0.55% 76

Other funds holding CDMO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
AltraVue Capital Bellevue, Washington $1.39B AUM 53.77% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
SCM
Snyder Capital Management San Francisco, California $5.79B AUM 33.56% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $2.3B AUM 29.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geneva Capital Management's CDMO Position: Q4 2023 in Review

Geneva Capital Management sold out of Avid Bioservices, Inc. Common Stock (CDMO) in Q4 2023, closing a stake of 2,258,671 shares — an estimated $21.3M sold.

Geneva Capital Management first reported a position in CDMO in Q1 2022 and held it in 7 quarters. The position peaked at $43.6M in Q1 2023. 175 funds tracked by Wall St. Rank hold CDMO as of Q4 2023.

  • Geneva Capital Management reported no remaining Avid Bioservices, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Geneva Capital Management sold 2,258,671 Avid Bioservices, Inc. Common Stock shares in Q4 2023, an estimated $21.3M.
  • Geneva Capital Management first reported a position in Avid Bioservices, Inc. Common Stock in Q1 2022 and held it in 7 quarters.
  • Geneva Capital Management's Avid Bioservices, Inc. Common Stock position peaked at $43.6M in Q1 2023.
  • 175 funds tracked by Wall St. Rank held Avid Bioservices, Inc. Common Stock as of Q4 2023.

Based on Geneva Capital Management's 13F filing for Q4 2023, filed 7 Feb 2024.